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Background: Cross-breeding of transgenic mice is commonly used to assess gene-gene interactions, particularly in
the context of disease. Strain background changes can influence the phenotype of mouse models and can
confound crossbreeding studies. We sought to determine if changing the strain background of a commonly used
mouse model of tauopathy (rTg4510) would significantly impact the originally reported phenotype. On the original
F1 FVB/N x 129S6 background, rTg4510 mice present with progressive cognitive decline, increased insoluble tau,
robust tau pathology and age-dependent neurodegeneration. One of the most common strains in mouse modeling
is C57BL/6. We and others have previously reported that this strain background alters the phenotypes of various
models, including the JNPL3 model of tauopathy. To determine if the phenotype of rTg4510 mice was similarly
affected by the introduction of the C57BL/6 background, we compared rTg4510 mice on the original F1 FVB/N x
129S6 background to rTg4510 mice on an F1 FVB/N x C57BL/6NTac (B6/NTac) background, herein termed rTg4510B6.
Results: Despite a small, but significant increase in soluble human tau levels, young rTg4510B6 mice had equivalent
levels of tau phosphorylation, aggregation and cognitive impairments as age-matched rTg4510 mice. At 6.5 months
of age, rTg4510B6 mice displayed hyperphosphorylated insoluble tau and robust cortical tau neuropathology that
was equivalent to age-matched rTg4510 mice; however, 10.5-month-old rTg4510B6 mice had greater amounts of
phospho-tau in the cortex and hippocampus when compared to age-matched rTg4510 mice. Non-transgenic (NT)
littermates of rTg4510B6 (NTB6) mice also had greater amounts of cortical and hippocampal phospho-tau at
10.5 months of age when compared to NT littermates of rTg4510 mice. Additionally, older rTg4510B6 mice had
gross forebrain neurodegeneration that was equivalent to age-matched rTg4510 mice.
Conclusions: Overall, our data shows that introduction of the C57BL/6 strain into the rTg4510 mouse background
modestly alters the tau pathology that was originally reported in rTg4510 on the F1 FVB/129 background. In
contrast, behavioral and neurodegenerative outcomes were not altered. These studies support the use of the
rTg4510 mouse model on a partial C57BL/6 strain background without losing fidelity of the phenotype and suggest
that the C57BL/6 background does not inherently protect against tauopathy.
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Numerous transgenic mice expressing wild-type or mutant
human tau have been created to model the neuropathology
of tauopathies–a group of neurodegenerative diseases char-
acterized by the accumulation of tau protein aggregates.
Many of the behaviors and pathologies reported for these
mouse models, even those that express the same tau pro-
tein, are different. Several factors may contribute to these
differences, including the levels and regions of transgenic
tau protein expression, the characteristics of the promoters
used to drive transgenic tau expression, and the behav-
ioral tests used to characterize the models. The strain
background of transgenic mice can also alter disease
progression and presentation.
JNPL3 [1] and rTg4510 [2] mice are two widely used,
independent mouse models of human tauopathy that
express the same human 0N4R tau protein using different
promoter systems. Previously, Bolmont et al. crossed the
JNPL3 mouse model from a mixed background onto an
inbred C57BL/6 J background and found that the regional
distribution of tauopathy was altered and that the timing
of phenotype was significantly delayed [3]. Studies have
also suggested that the C57BL/6 background is protective
against neurotoxicity in other disease models [4-7]. To test
the hypothesis that crossing rTg4510 mice to a C57BL/6
strain background is protective against tauopathy, we have
compared rTg4510 mice on the original F1 FVB/N x 129S6
background to rTg4510 on an F1 FVB/N x C57BL/6NTac
background (rTg4510B6) (Figure 1). Here we compare theFigure 1 Breeding scheme for comparison of rTg4510 mice on differe
mice on an F1 FVB/N x C57BL/6 (FVB/B6) strain background (rTg4510B6) (Le
(FVB/129) strain background (Right). Mice used in these studies include rTg
tTA activator transgenes and non-transgenic (NTB6 and NT) mice. Single tra
these studies.phenotypes of both young and old rTg4510 mice on each
strain background.
Results
Increased human tau levels in young rTg4510B6 mice
Tau is normally a highly soluble protein and expression
levels are generally measured in soluble protein extracts.
In order to compare human tau expression levels in
rTg4510B6 and rTg4510 mice, we prepared soluble brain
extracts from mice at 2.5 months of age, prior to robust
tau pathology and neuronal loss. rTg4510B6 mice had
a small, but significant increase (0.32 ± 0.13; p < 0.05)
in soluble human tau levels compared to rTg4510 mice at
2.5 months of age, suggesting that rTg4510B6 mice
may have moderately elevated tau transgene expression
(Figure 2). Using the Tau5 antibody that recognizes both
the transgenic human tau and endogenous mouse tau,
no differences in soluble total tau levels were found be-
tween rTg4510B6 and rTg4510 mice at 2.5 months of age.
Human tau expression in the rTg4510 lines is controlled
by the tetracycline transactivator (tTA). Although both the
tTA129 mice used for rTg4510 mice and the tTAB6 mice
used for rTg4510B6 mice originated from the same tTA line
[8], this minor increase in tau expression could be due to
minor changes in tTA expression on the two backgrounds.
We were, however, unable to assess tTA expression
due to the lack of a good tTA antibody, a problem that
is consistent with data from others working with tTA
mouse lines [5,9,10].nt strain backgrounds. Breeding scheme used to produce rTg4510
ft) compared to the original rT4510 mice on an F1 FVB/N x 129S6
4510B6 and rTg4510 mice that carry both the tau responder and the
nsgenic mice generated from these F1 crosses were not analyzed in
Figure 2 2.5-month-old rTg4510B6 mice have increased human tau expression compared to rTg4510 mice. (A-B) Western blot analyses of
the soluble fractions of whole brain lysates from rTg4510B6 and rTg4510 mice at 2.5 months of age. (A) Representative western blots of soluble
human tau (E1 antibody), human and mouse tau (Tau5 antibody), and phosphorylated tau (CP13 and PHF1 antibodies) with a NT littermate
shown as a negative control. (B) Densitometric quantification of E1 (human tau), Tau5 (human and mouse tau), CP13 (pS202 tau) and PHF1
(pS396/404 tau) normalized to GAPDH. rTg4510B6 mice had increased soluble human tau, indicating greater tau transgene expression than
age-matched rTg4510 mice. No differences in soluble phospho-tau levels were detected using CP13 and PHF1 antibodies. Each dot represents an
individual mouse with the mean indicated by the black line. n = 9-10 per cohort. *P < 0.05 (Student’s t-test).
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rTg4510B6 and young rTg4510 mice
Normal tau function and solubility is regulated by phos-
phorylation (reviewed in [11]); therefore, we compared the
phosphorylation of soluble tau in young rTg4510 mice on
both strain backgrounds. To detect tau phosphorylated at
S202 and S396/404–sites that are hyper-phosphorylated in
human tauopathies–we used the phospho-tau antibodies
CP13 and PHF1, respectively [2,12-14]. Analysis of soluble
brain extract with the CP13 and PHF1 antibodies revealed
that young rTg4510B6 mice had similar phosphorylation of
soluble tau as rTg4510 mice (Figure 2).A central feature of human tauopathies is the loss of tau
solubility and the accumulation of hyper-phosphorylated
tau in aggregates that can be isolated from brain with
sarkosyl extraction [15]. Tau deposition in the sarkosyl-
insoluble brain fraction can be detected as early as
2.5 months of age in rTg4510 mice. With increasing
age and disease progression, insoluble tau shifts from
a ~55 kDa species to a hyper-phosphorylated 64 kDa
species [14] and we have previously demonstrated that
64 kDa tau is biochemically equivalent to NFTs in tau
transgenic mice [1]. At 2.5 months of age, there was no
significant difference in the accumulation of insoluble
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rTg4510B6 mice compared to rTg4510 mice (Figure 3).
Importantly, we observed the initial aggregation of a
64 kDa tau species in rTg4510 mice on either strain
background. There was considerable spread in the degree
of insoluble tau found within each group, consistent with
each animal being in slightly different stages of the initial,
rapid development of tauopathy. We also examined the
insoluble fraction with the Tau5 antibody, but were unable
to obtain sufficient Tau5 antibody reactivity with the insol-
uble fraction from 2.5 month-old rTg4510 mice on either
strain background (data not shown).
Comparable cognitive deficits in young rTg4510B6 and
rTg4510 mice
The initial characterization of rTg4510 mice showed that
human tau expressing mice had similar motor perform-
ance to tau negative mice on the F1 FVB/129S strain
background at 2.5 months of age, before widespread
neurodegeneration in the brain [10]. Studies have shown,
however, that non-transgenic (NT) mice on different
strain backgrounds can have variable motor performanceFigure 3 Equivalent accumulation and phosphorylation of insoluble t
blot analyses of the sarkosyl-insoluble fractions of whole brain lysates from
western blots of insoluble human tau (E1 antibody) and phosphorylated ta
control. (B) Densitometric quantification of E1 (human tau), CP13 (pS202 ta
amount of human tau aggregated in that fraction. Insoluble tau accumulat
mice. Each dot represents an individual mouse with the mean indicated byin a variety of behavioral tasks [16]. To assess effects of
the C57BL/6 strain background on sensorimotor function,
2.5-month-old rTg4510B6, rTg4510 and NT mice on both
strain backgrounds performed the cued (visible platform)
version of MWM. No differences in swim speed were
observed across training between all groups (Figure 4A).
Further, all groups improved performance over training,
as indicated by the decreased search path to the platform
[F (2, 32) = 35.91, p < 0.001], but rTg4510 mice on both
strain backgrounds had longer search paths to reach
the platform than NT mice [F (1, 16) = 5.39, p < 0.05]
(Figure 4B). Post hoc analysis revealed that by the third day
of visible platform training, all groups swam comparable
distances to reach the platform. Equivalent results were
found with measurements of the escape latency to reach
the platform (data not shown). Importantly, no differences
between strains were detected, signifying that mice on an
F1 FVB/B6 background had similar sensorimotor function
as mice on the F1 FVB/129 background.
Spatial learning and reference memory are hippocampal
dependent functions [17]. The hippocampus is one of the
first regions affected by tauopathy in rTg4510 mice andau in 2.5-month-old rTg4510B6 and rTg4510 mice. (A-B) Western
rTg4510B6 and rTg4510 mice at 2.5 months of age. (A) Representative
u (CP13 and PHF1 antibodies) with a NT littermate shown as a negative
u) and PHF1 (pS396/404 tau). Phospho-tau is normalized to the
ion and phosphorylation were similar between rTg4510B6 and rTg4510
the black line. n = 9-10 per cohort.
Figure 4 Strain background does not alter swim speed or search path in the MWM. (A-B) Performance in the cued MWM task was
equivalent amongst rTg4510 and NT littermates on either strain background at 2.5 months of age. (A) Swim speeds to the visible platform were
equivalent across all groups. (B) All groups improved performance over training (p < 0.001) with the search paths to reach the visible platform
longer for rTg4510 mice on days 1 and 2, but comparable to NT mice by day 3. No differences between strain backgrounds were detected. Data
expressed as mean ± SEM and analyzed via multifactorial (genotype x strain) RM ANOVA with post hoc Bonferonni’s multiple comparisons test.
n = 5 per cohort.
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are detected as early as 2.5 months of age in rTg4510
on the original F1 FVB/129 strain background [2,14].
Analysis of our 2.5-month-old rTg4510 and NT co-
horts showed improvement in finding the hidden plat-
form for all groups across training days [escape latency:
F (4, 64) = 8.43, p < 0.001), search path: F (4, 64) = 5.77,
p < 0.001] (Figure 5A-B). rTg4510 mice showed signifi-
cantly less improvement in performance than NT mice
as indicated by longer escape latencies [F (1, 16) = 61.78,
p < 0.001)] (Figure 5A) and longer search paths to find the
hidden platform [F(1, 16) = 48.83, p < 0.001)] (Figure 5B).
Additionally, no strain background effect was detected
for either parameter. Irrespective of strain background,
rTg4510 mice showed increased thigmotaxic, or wall-
hugging, swimming compared to NT mice [F (1, 16) =
24.70, p < 0.001]. The thigomotaxic behavior of rTg4510
mice decreased over training days [F (4, 64) = 19.07,
p < 0.001]; however, it never reached the low levels of
thigomotaxis observed in NT mice (Figure 5C). Spatial
learning performance was also assessed by the percent-
age of distance swam in the target quadrant during the
final probe trial–rTg4510 mice on both strain back-
grounds were significantly impaired compared to NT
mice (p < 0.0001) (Figure 5D). Overall, we found that
crossing rTg4510 mice to a C57BL/6 strain background
did not affect sensorimotor function or attenuate the
cognitive decline that is characteristic of rTg4510 mice
on the original strain background at 2.5 months of age.
Characterization of tau in older rTg4510B6 brain extracts
Having found that the onset of tauopathy is unchanged in
rTg4510B6 mice compared to the original rTg4510 mice,we then sought to determine if the C57BL/6 background
alters late stage tauopathy in mice at 6.5 and 10.5 months
of age. Unlike young mice, old rTg4510B6 mice had similar
levels of soluble human tau and increased levels of total sol-
uble tau (human and mouse) as rTg4510 mice (p < 0.01)
(Figure 6). Further, while there was not a significant differ-
ence in the phosphorylation of soluble tau detected with
CP13, analysis with PHF1 revealed that old rTg4510B6 mice
had twice as much soluble tau phosphorylated at S396/404
compared to old rTg4510 mice (p < 0.01) (Figure 6). By late
stage tauopathy, rTg4510 mice were characterized primarily
by a 64 kDa species of tau in the sarkosyl-insoluble brain
fraction, regardless of strain background and the accumu-
lation of human tau in the insoluble fraction was similar
between rTg4510B6 and rTg4510 mice (Figure 7). The
accumulation of human and mouse tau in the sarkosyl-
insoluble fraction, as assessed with the Tau5 antibody,
was also similar between rTg4510B6 and rTg4510 mice
(data not shown). The 64 kDa insoluble tau band from
rTg4510 mice on either background was similarly phos-
phorylated at epitopes associated with human tauopathy
when normalized to the amount of human tau (Figure 7)
or human and mouse tau (data not shown) in the sarkosyl-
insoluble fraction. Results from the biochemical analysis of
tau in older rTg4510B6 and rTg4510 mice are summarized
in Table 1.
rTg4510B6 mice have increased tau pathology compared
to rTg4510 mice
Immunohistochemical (IHC) staining with CP13 and PHF1
antibodies was used to compare tauopathy in rTg4510B6
and rTg4510 mice. Both CP13 and PHF1 detected striking
amounts of tauopathy in the cortex and hippocampus of
Figure 5 rTg4510B6 and rTg4510 mice have equivalent cognitive deficits at 2.5 months of age. Spatial learning and memory was
equivalently impaired in rTg4510B6 and rTg4510 mice at 2.5 months of age. (A) rTg4510 mice took significantly more time to find the hidden
platform than NT mice (p < 0.001), with no difference between the strain backgrounds. (B) The search paths to reach the hidden platform for
both rTg4510B6 and rTg4510 mice were equivalent and significantly longer than the search paths of NT mice (p < 0.001). (C) rTg4510B6 and
rTg4510 mice also had similar thigmotaxic swimming that was significantly longer than that of NT mice (p < 0.001). (D) Spatial memory was
equally impaired in rTg4510B6 and rTg4510 mice compared to age-matched NT mice as indicated by the decreased percentage of distance
traveled in the target quadrant (TQ) during the final probe trial. (A-C) Data expressed as mean ± SEM and analyzed via multifactorial (genotype x
strain) RM ANOVA. (D) Each dot represents an individual mouse with the mean indicated by the black line. ****p < 0.0001 [two-way ANOVA
(genotype x strain): main effect of genotype indicated]. n = 5 per cohort.
Bailey et al. Molecular Neurodegeneration 2014, 9:8 Page 6 of 20
http://www.molecularneurodegeneration.com/content/9/1/8late stage rTg4510 mice on either background and tau path-
ology was found in both the cell body and the neuropil
(Figures 8 and 9). The brainstem was minimally affected,
reflecting the low levels of transgenic tau expression
within this brain structure (Figures 8 and 9). Results
from a two-way ANOVA (strain background x age) in-
dicated that rTg4510B6 mice had increased cortical
CP13-specific phospho-tau compared to rTg4510 mice
[F (1, 13) = 8.60, p < 0.05], but there was an interaction
of strain background and age [F (1, 13) = 8.40, p < 0.05]
(Figure 8, Table 2). Post hoc analysis revealed that cor-
tical CP13 burden was increased in rTg4510B6 mice at
10.5 months of age (p < 0.01), but not 6.5 months of
age when compared to age-matched rTg4510 mice. In-
dependent of age, CP13 burden was also significantly
higher in the hippocampus of rTg4510B6 mice compared
to rTg4510 mice [F (1, 13) = 15.00, p < 0.01] (Figure 8,
Table 2). We also analyzed the brainstem of rTg4510B6
and rTg4510 mice and found that CP13 staining was
increased with age but unaffected by the strain backgroundof the mice (Figure 8, Table 2). Quantitation of regional
PHF1 staining yielded similar results. Cortical PHF1
staining was increased in rTg4510B6 mice compared to
rTg4510 mice [F (1, 13) = 9.20, p < 0.01], but there was an
interaction of strain background and age [F (1, 13) = 9.40,
p < 0.01] with PHF1 burden being significantly higher in
rTg4510B6 mice over rTg4510 mice only at 10.5 months
of age (p < 0.01) (Figure 9, Table 2). Additionally, PHF1
was significantly increased in the hippocampus of
rTg4510B6 mice compared to rTg4510 mice at both 6.5
and 10.5 months of age [F (1, 13) = 23.00, p < 0.001]
(Figure 9). Interestingly, there was also increased PHF1
immunoreactivity that was not seen with CP13 in the
brainstem of rTg4510B6 mice when compared to rTg4510
mice on the original strain background [F (1, 13) = 21.00,
p < 0.001] (Figure 9, Table 2). Overall, IHC analysis
revealed age-dependent regional differences in phospho-
tau pathology in mice crossed to a C57BL/6 back-
ground compared to mice on the original rTg4510 strain
background.
Figure 6 Older rTg4510B6 mice have increased soluble Tau5 and PHF1 levels compared to rTg4510 mice. (A-B) Western blot analyses of
the soluble fractions of whole brain lysates from 6.5- and 10.5-month-old rTg4510B6 and rTg4510 mice. (A) Representative western blots of
soluble human tau, human and mouse tau, and phosphorylated tau and with a NT littermate shown as a negative control. (B) Densitometric
quantification of E1 (human tau), Tau5 (human and mouse tau), CP13 (pS202 tau) and PHF1 (pS396/404 tau) normalized to GAPDH. rTg4510B6
mice had equivalent levels of soluble CP13 and human tau, and increased soluble total tau (human and moues) and PHF1 tau compared to
rTg4510 mice on the original strain background. Each dot represents an individual mouse with the mean indicated by the black line. n = 3-4 per
cohort. **p < 0.01 [two-way ANOVA (strain x age): main effect of strain indicated].
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strain background
As human tau transgene expression in the brainstem of
the original rTg4510 mice is very low, it was surprising
to detect increased PHF1 staining in the brainstem of
old rTg4510B6 mice. The PHF1 antibody recognizes both
phosphorylated human and mouse tau; therefore, it was
possible that that addition of C57BL/6 into the strain
background could increase phosphorylation of endogen-
ous mouse tau. To test this, we analyzed PHF1 staining
in NT mice on both the F1 FVB/B6 (NTB6) and the F1
FVB/129 (NT) strain backgrounds. Similarly to rTg4510
mice, PHF1 staining was increased in the cortex of NTB6mice compared to NT mice [F (1, 14) = 18.00, p < 0.001],
but there was an interaction of strain background and
age [F (1, 14) = 14.00, p < 0.01] with PHF1 burden being
significantly higher in NTB6 mice over NT mice only at
10.5 months of age (p < 0.001) (Figure 10, Table 3).
Additionally, PHF1 staining was significantly increased
in the hippocampus and brainstem of NTB6 mice com-
pared to NT mice at both time points and independent
of an interaction with age [hippocampus: F (1, 14) =
33.00, p < 0.0001; brainstem: F (1, 14) = 40.00, p < 0.0001]
(Figure 10, Table 3). Analysis with the CP13 antibody
revealed that old NTB6 mice had significantly more CP13
staining in the cortex [F (1, 14) = 9.90, p < 0.01], but not in
Figure 7 Accumulation and phosphorylation of insoluble tau is not significantly changed in older rTg4510B6 mice. (A-B) Western blot
analyses of the sarkosyl-insoluble fractions of whole brain lysates from rTg4510B6 and rTg4510 mice at 6.5 and 10.5 months of age. (A) Representative
western blots of insoluble human and phosphorylated tau with a NT littermate shown as a negative control. (B) Densitometric quantification of
E1 (human tau), CP13 (pS202 tau) and PHF1 (pS396/404 tau). Phospho-tau is normalized to the amount of human tau aggregated in that
fraction. Each dot represents an individual mouse with the mean indicated by the black line. n = 3-4 per cohort.
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(data not shown, Table 3).
Equivalent neurodegeneration in old rTg4510B6 and
rTg4510 mice
A pathological hallmark of rTg4510 mice is age-dependent
neurodegeneration of the forebrain regions that is detectedTable 1 Two-way ANOVA of strain background and age effec
rTg4510B6 mice compared to rTg4510 mice
Strain Background
Fraction stain F (DFn, DFd) P value F (D
Soluble E11 F (1, 10) = 3.60 P = 0.09 F (1,
Soluble Tau51 F (1, 10) = 11.00 P < 0.01 F (1,
Soluble CP131 F (1, 10) = 2.40 P = 0.15 F (1,
Soluble PHF11 F (1, 10) = 20.00 P < 0.01 F (1,
Insoluble E1 F (1, 10) = 3.90 P = 0.08 F (1,
Insoluble Tau5 F (1, 10) = 2.70 P = 0.13 F (1,
Insoluble CP132 F (1, 10) = 3.60 P = 0.09 F (1,
Insoluble PHF12 F (1, 10) = 0.04 P = 0.85 F (1,
1Normalized to GAPDH; 2Normalized to insoluble E1.by 5.5 months of age [2,14]. Consistent with this, 6.5-and
10.5-month-old rTg4510 mice on both strain backgrounds
had significantly lower hemi-brain weights than NT mice
[F (1, 24) = 158.72, p < 0.001] (Figure 11A). There was also
a small, but significant decrease in the brain weight of all
mice on an F1 FVB/B6 background compared to all mice
on the original F1 FVB/129 background [F (1, 24) = 4.60,ts on soluble and insoluble tau in 6.5 and 10.5 month-old
Age Interaction
Fn, DFd) P value F (DFn, DFd) P value
10) = 3.20 P = 0.10 F (1, 10) = 0.94 P = 0.36
10) = 3.20 P = 0.10 F (1, 10) = 0.05 P = 0.82
10) = 0.06 P = 0.81 F (1, 10) = 0.25 P = 0.63
10) = 4.80 P = 0.05 F (1, 10) = 0.57 P = 0.47
10) = 0.002 P = 0.97 F (1, 10) = 0.002 P = 0.97
10) = 1.20 P = 0.29 F (1, 10) = 0.50 P = 0.50
10) = 0.29 P = 0.60 F (1, 10) = 0.06 P = 0.81
10) = 2.90 P = 0.12 F (1, 10) = 0.75 P = 0.41
Figure 8 (See legend on next page.)
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Figure 8 Older rTg4510B6 mice have region-specific increases in CP13 compared to rTg4510 mice. rTg4510B6 mice had increased CP13
(pS202 tau) staining in the cortex and hippocampus, but not the brainstem regions of the brain compared to rTg4510 mice at 10.5 months of
age. (A) Representative images of cortical, hippocampal and brainstem regions of 6.5- and 10.5-month-old rTg4510B6 and rTg4510 mice stained
with the CP13 antibody. (B) Quantitative analyses of the stained sections showed that the CP13 burden in the cortex of rTg4510B6 mice was
significantly greater than the corresponding regions of rTg4510 mice at 10.5 months, but not 6.5 months of age, and increased in the
hippocampus of rTg4510B6 at both age points. Each dot represents an individual mouse with the mean indicated by the black line, n = 3-5 per
cohort. ***p < 0.001 [two-way ANOVA (strain x age): main effect of strain indicated]. ##p < 0.01 (post hoc Bonferonni’s multiple comparisons test).
Scale bar represents 200 μm.
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wanted to determine if there were differences in the size
of regions specifically vulnerable to tau-related neurode-
generation in this model. Neuronal loss in forebrain re-
gions of rTg4510 mice has been well characterized by
work from Spires et al. that used stereological methods
to demonstrate that the overall hippocampal formation
has the greatest neuronal loss when compared to the
cortical and striatal regions [18]. To assess hippocampal
atrophy in rTg4510B6 mice, we measured the area of the
hippocampal formation in matched sagittal sections of
6.5-and 10.5-month-old rTg4510 mice and NT littermates
on both strain backgrounds. Three factor ANOVA
(age x strain x genotype) revealed that the area of the
hippocampi were significantly affected by age, strain
background and genotype [age: F (1, 27) = 7.57, p < 0.01;
strain: F (1, 27) = 5.07, p < 0.05; genotype: F (1, 27) = 501.97,
p < 0.001], and that there was an interaction between all
three factors [F (1, 27) = 5.93, p < 0.05]. Post hoc analysis
revealed that both 6.5-and 10.5-month-old rTg4510
mice had significantly smaller hippocampal areas com-
pared to NT mice (ps < 0.0001), with no difference in
size between rTg4510 mice on the original strain back-
ground and rTg4510B6 mice (Figure 11B). Additionally,
at 6.5 months of age the area of the hippocampi in NTB6
mice was significantly smaller than NT mice (p < 0.01),
but this difference was abrogated by 10.5 months of age
(Figure 11B). We also examined the CA1 layer, as this
hippocampal sub-region has been reported to have an 82%
reduction of neurons by 8.5 months of age in rTg4510 mice
on the original strain background [18]. We calculated a
CA1 index value for each mouse with a smaller index value
indicating fewer CA1 neurons (see Methods). In agree-
ment with previous data by Spires et al. [18], we found
that rTg4510 mice had significantly smaller CA1 indices
than NT mice [F (1, 27) = 96.54, p < 0.001], suggesting
that rTg4510 mice have greater neuronal loss (Fig-
ure 11C). Additionally, there was no difference between
strains, although the CA1 index value was found to sig-
nificantly decreased with age [F (1, 27) = 8.67, p < 0.01],
consistent with progressive neuronal loss previously
reported in this model. Overall, histological analyses of
rTg4510B6 brains at 6.5 and 10.5 months of age revealed
substantial thinning of the neuronal cell layers of the CA1and dentate gyrus hippocampal sub-regions, gross atrophy
of the hippocampi and cortices and ventricle enlargement
that was indistinguishable from age matched rTg4510
mice (Figure 11D).
Discussion
rTg4510 mice that overexpress mutant human tau are
widely used in both academia and industry to study
modifiers of human tauopathy [19-33], yet rTg4510 mice
on a different strain background have not been fully char-
acterized. One of the most commonly used mouse strains
is C57BL/6 and crossing to this background can affect a
mouse model’s phenotype because of genetic and behav-
ioral differences that exist amongst inbred mouse strains
(reviewed in [34]). In this study we analyzed rTg4510 mice
on a C57BL/6NTac background (rTg4510B6) near the onset
of tauopathy at 2.5 months of age and during late stage
tauopathy at 6.5 and 10.5 months of age. We found that at
2.5 months of age, rTg4510B6 mice had a small, but signifi-
cant increase in soluble human tau levels and equivalent
tau phosphorylation and aggregation as compared to age-
matched rTg4510 mice on the original strain background.
Further, cognition was equally impaired in young rTg4510B6
and rTg4510 mice as compared to NT littermates. During
late stage tauopathy, rTg4510B6 mice displayed hyperpho-
sphorylated insoluble tau and robust neurodegeneration
that was equivalent to rTg4510 mice. Additionally, sol-
uble phospho-tau detected with the PHF1 antibody was
increased in rTg4510B6 mice compared to rTg4510 mice
and 10.5-month-old rTg4510B6 mice had greater amounts
of phospho-tau in the cortex and hippocampus when com-
pared to age-matched rTg4510 mice. Finally, NT littermates
of rTg4510B6 mice also had greater amounts of cortical and
hippocampal phospho-tau at 10.5 months of age compared
to NT littermates of rTg4510 mice. Interestingly, aged
rTg4510 and NT mice containing a C57BL/6 background
had greater variation in measured phospho-tau levels,
therefore, a greater number of mice are needed to con-
firm that the findings of aged rTg4510B6 mice were not
influenced by an outlier.
Contrary to our findings with rTg4510 mice, previous
work with JNPL3 mice showed that backcrossing onto
C57BL/6 strain background significantly delayed the
onset of disease and altered the pathological presentation
Figure 9 (See legend on next page.)
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Figure 9 Increased PHF1 tau staining in multiple brain regions of older rTg4510B6 mice. Older rTg4510B6 mice had increased PHF1
(pS396/404 tau) staining compared to rTg4510 mice in the cortex, hippocampus and brainstem regions of the brain. (A) Representative images of
cortical, hippocampal and brainstem regions from 6.5-and 10.5-month-old rTg4510B6 and rTg4510 mice stained with the PHF1 antibody.
(B) Quantitative analyses of the stained sections showed that the PHF1 burden was significantly greater in the cortex of rTg4510B6 mice at
10.5 months and in the hippocampus and brainstem at both 6.5 and 10.5 months of age compared to the corresponding regions of rTg4510
mice. Each dot represents an individual mouse with the mean indicated by the black line, n = 3-5 per cohort. ***p < 0.001 [two-way ANOVA
(strain x age): main effect of strain indicated]. ##p < 0.01 (post hoc Bonferonni’s multiple comparisons test). Scale bars represent 200 μm.
CC = Corpus callosum; 7 N = 7th Cranial nerve.
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the same P301L 0N4R tau as rTg4510 mice, there are sev-
eral important differences between the models that may
explain the disparate effects of the C57BL/6 strain on
tauopathy in each model. The tau transgenic integration
sites in JNPL3 and rTg4510 mice have not been published,
but it is likely that the incorporation of the human tau
cDNA into the murine genome occurred at different loca-
tions for each model. Based on the integration site of the
transgenes and the endogenous activity of that chromo-
somal region, strain background could differentially affect
promoter activity in each model [35]. Moreover, the trans-
genic tau expression in JNPL3 mice is controlled by the
mouse prion promoter, resulting in human mutant tau
that predominantly affects neurons in the spinal cord and
hindbrain. In contrast, tau expression in rTg4510 mice is
ultimately controlled by the CaMKIIα promoter, which re-
sults in high tau expression in neurons in the forebrain re-
gion. The promoter affects which populations of neurons
are expressing the transgene and different neuronal popu-
lations may be differently affected in each strain back-
ground. Additionally, the C57BL/6 sub-strain utilized in
each study could also contribute to the difference. In this
study, we crossed tau-expressing mice to a C57BL/6NTac
(B6/NTac) sub-strain while Bolmont et al. crossed tau-
expressing mice to a C57BL/6 J (B6/J) sub-strain. The B6/
NTac sub-strain from Taconic was originally derived from
the B6/J strain from Jackson laboratory, but over time
genetic and phenotypic differences have developed be-
tween the two sub-strains [36-38]. Although we detected
significant, but relatively modest changes in the tauopathyTable 2 Two-way ANOVA of strain background and age effec
rTg4510B6 mice compared to rTg4510 mice
Strain background
Region stain F(DFn, DFd) P value F(DF
Cortex CP13 F (1, 13) = 8.60 P < 0.05 F (1, 1
Cortex PHF1 F (1, 13) = 9.20 P < 0.001 F (1, 1
Hipp CP13 F (1, 13) = 15.00 P < 0.01 F (1, 1
Hipp PHF1 F (1, 13) = 23.00 P < 0.001 F (1, 1
BS CP13 F (1, 13) = 1.20 P = 0.29 F (1, 1
BS PHF1 F (1, 13) = 21.00 P < 0.001 F (1, 1of rTg4510 mice on a B6/NTac background, it is possible
that modifiers of tauopathy exist on the B6/J strain. Finally,
the C57BL/6 strain zygosity has been shown to affect trans-
genic phenotype [4,5] and the Bolmont et al. study used
congenic C57BL/6 mice while our studies used hybrid
F1 C57BL/6 mice. If a recessive gene were responsible
for altering tauopathy in JNPL3, such effects would not
be detected in F1 rTg4510B6 mice.
In addition to the concerns detailed above, differences
in transgenic protein levels could confound compari-
sons of the same model on different strain backgrounds
(i.e. rTg4510B6 vs. rTg4510). By comparing tau protein
levels between rTg4510B6 and rTg4510 mice prior to
substantial neuronal loss, we found that rTg4510B6 mice
have a small, but significant, increase in soluble human
tau. Interestingly, this difference in soluble human tau
levels was not detected using an antibody specific for
both human and mouse tau, which may reflect a differ-
ence in endogenous tau levels between the two strain
backgrounds. It should be noted though, that it is cur-
rently unclear if the Tau5 antibody has equal affinity for
human and mouse tau, confounding such an interpret-
ation. Increased soluble human tau in young rTg4510B6
mice could result from decreased tau degradation or from
increased tau transgene expression. Because the tau re-
sponder line utilized in the rTg4510B6 and rTg4510
lines were identical, it is unlikely that the difference in
transgenic tau expression arose from the tau responder
line, per se. Since human tau expression in the rTg4510
model is dependent on both the tau and the tTA trans-
genes, elevated levels of tTA expression could underlie thets on phospho-tau burden in 6.5 and 10.5 month-old
Age Interaction
n, DFd) P value F(DFn, DFd) P value
3) = 0.08 P = 0.78 F (1, 13) = 8.40 P < 0.05
3) = 0.05 P = 0.83 F (1, 13) = 9.40 P < 0.001
3) = 0.05 P = 0.83 F (1, 13) = 1.00 P = 0.33
3) = 0.03 P = 0.88 F (1, 13) = 1.40 P = 0.26
3) = 9.90 P < 0.01 F (1, 13) = 2.80 P = 0.12
3) = 1.10 P = 0.32 F (1, 13) = 0.43 P = 0.52
Figure 10 (See legend on next page.)
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Figure 10 Increased PHF1 staining in older NTB6 mice compared to NT mice. NT mice on an F1 FVB/B6 background (NTB6) had increased
PHF1 (pS396/404 tau) staining in the cortex, hippocampus and brainstem regions of the brain compared to NT mice on an F1 FVB/129
background (NT). (A) Representative images from the primary sensory cortex, hippocampal formation and brainstem of NTB6 and NT mice stained
with PHF1. (B) Quantification of PHF1 burden in the cortex, hippocampus, and brainstem of 6.5- and 10.5-month-old NTB6 and NT mice. Cortical
PHF1 staining was significantly increased in NTB6 mice compared to NT mice only at 10.5 months of age, while at 6.5 and 10.5 months of age
PHF1 burden was increased in the hippocampal formation and brainstem. Each triangle represents an individual mouse with the mean indicated
by the black line, n = 3-7 per cohort. ***p < 0.0001 [two-way ANOVA (strain x age): main effect of strain indicated]. ###p < 0.001
(post hoc Bonferonni’s multiple comparisons test). Scale bars represent 200 μm. CC = Corpus callosum; 7 N = 7th Cranial nerve.
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in rTg4510 and rTg4510B6 mice originated from the same
line and laboratory [8] and they were subsequently back-
crossed to different mouse strains by the two different la-
boratories from which we acquired the mice. It is possible
that change of transgene copy number may have occurred
between the two tTA sub-lines, and this could influence
our findings. This can occur if there is inherent instability
of the transgene locus [39]. We attempted to use commer-
cially available antibodies raised against tTA to determine
if tTA levels were changed between rTg4510B6 and
rTg4510 mice, but like others, we were unsuccessful in
detecting tTA protein using these antibodies [5,9,10].
We, therefore, were unable to determine if altered tTA
expression underlies the modestly increased tau levels
in young rTg4510B6 mice.
Despite increased human tau expression in 2.5-month-
old rTg4510B6 mice, we did not detect differences in tau
phosphorylation or aggregation at this age. Furthermore,
rTg4510B6 and rTg4510 mice were similarly cognitively
impaired. The hidden platform version of MWM revealed
that cognition was equivalently impaired in 2.5-month-old
rTg4510 mice across strain backgrounds. Interestingly,
performance in the cued version of the MWM task
showed a difference in the swim path to the visible platform
between rTg4510 and NT mice across all days. Closer
analysis of individual training days revealed that although
rTg4510 mice on both backgrounds took significantly
longer paths to reach the platform on days 1 and 2, by
day 3 they performed comparably to NT littermates.
This suggests that rTg4510 mice took a longer time toTable 3 Two-way ANOVA of strain background and age effec
mice compared to NT mice
Strain background
Region stain F(DFn, DFd) P value F(DF
Cortex CP13 F (1, 14) = 9.90 P < 0.01 F (1,
Cortex PHF1 F (1, 14) = 18.00 P < 0.001 F (1,
Hipp CP13 F (1, 14) = 1.30 P = 0.28 F (1,
Hipp PHF1 F (1, 14) = 33.00 P < 0.0001 F (1,
BS CP13 F (1, 14) = 0.03 P = 0.86 F (1,
BS PHF1 F (1, 14) = 40.00 P < 0.0001 F (1,learn the cue, but once learned, were able to perform
comparably to NT mice so that the deficits observed in
rTg4510 mice on both backgrounds strains can be
accredited to cognitive deficits rather than an inability to
complete the task. Overall, although behavioral differences
have been reported between C57BL/6 and 129S6 inbred
strains [40,41], we found no differences in sensorimotor
function or spatial dependent learning in mice of the same
genotype and on an F1 FVB/B6 versus an F1 FVB/129
strain background.
Interestingly, aged (6.5-and 10.5-month-old) rTg4510B6
mice did not have significantly different human tau levels,
as evaluated by soluble human tau. Total soluble tau levels,
though, were significantly increased in aged rTg4510B6 mice
as compared to rTg4510 mice when an antibody specific to
both human and mouse tau was used. Assessment of tau
protein production in old mice, however, is complicated by
significant neurodegeneration as those neurons expressing
human tau are likely the neurons that have died or will die.
Given this, the modest but significantly elevated levels of
human tau expression in the 2.5-month-old rTg4510B6
mice compared to rTg4510 are likely to be more accurate.
In old mice, the biochemical analysis of tau revealed
increased phospho-tau in the soluble brain fraction of
rTg4510B6 mice compared to rTg4510 mice using the
PHF1 antibody. Additionally, IHC analysis revealed that
PHF1 staining was increased in both the forebrain and
hindbrain of rTg4510B6 mice, while CP13 burden was in-
creased in forebrain regions (cortex and hippocampus),
but not in the brainstem of old rTg4510B6 mice compared
to old rTg4510 mice. Furthermore, NTB6 mice also hadts on phospho-tau burden in 6.5 and 10.5 month-old NTB6
Age Interaction
n, DFd) P value F(DFn, DFd) P value
14) = 1.50 P = 0.24 F (1, 14) = 3.30 P = 0.09
14) = 9.30 P < 0.01 F (1, 14) = 14.00 P < 0.01
14) = 0.04 P = 0.84 F (1, 14) = 0.01 P = 0.92
14) = 0.32 P = 0.58 F (1, 14) = 4.50 P = 0.05
14) = 0.28 P = 0.61 F (1, 14) = 3.20 P = 0.10
14) = 9.80 P < 0.01 F (1, 14) = 1.20 P = 0.29
Figure 11 (See legend on next page.)
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Figure 11 Older rTg4510B6 mice have equivalent gross neurodegeneration. Gross brain and hippocampal atrophy was equivalent in
rTg4510B6 and rTg4510 mice at 6.5 and 10.5 months of age. (A) All mice on an F1 FVB/B6 background had smaller hemi-brains than all mice on
an F1 FVB/129S background (p < 0.05). Independent of strain background, hemi-brain weights for rTg4510 mice were significantly decreased
compared to NT mice. (B) Hippocampal atrophy, as assessed by decreased hippocampal area, was significantly increased in age-matched rTg4510
mice compared to NT littermates, with no difference between rTg4510 mice on different strain backgrounds. (C) rTg4510B6 and rTg4510 mice
had similar CA1 index values that were significantly less than that of NT mice, indicating increased neuronal loss in the CA1 hippocampal
sub-region. (D) Overall, rTg4510 mice had gross atrophy of the forebrain and ventricle enlargement compared to NT mice that was indistinguishable
between age-matched rTg4510 mice on different strain backgrounds. In rTg4510 mice, the hippocampal formation was visibly reduced in size
with substantial thinning of the neuronal layers in the CA1 and dentate gyrus sub-regions. (A-C) Each dot represents an individual mouse with
the mean indicated by the black line. Data was analyzed via multifactorial (age x genotype x strain) ANOVA. ***p < 0.001 (main effect of genotype indicated).
n = 2-7 per cohort. Scale bars represent 200 μm.
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mice that was spatiotemporally parallel to the increased
PHF1 and CP13 staining in rTg4510B6 mice versus rTg4510
mice. Importantly, analysis of 64 kDa tau in the bio-
chemically abnormal, sarkosyl-insoluble fraction and
gross assessments of neurodegeneration through hemi-
brain weights, hippocampal areas, and CA1 neuronal
thickness, indicated no differences between rTg4510 mice
on different strain backgrounds. Taken together, these
results suggest that the differences we observed in sol-
uble phosphorylated tau levels and phospho-tau burden
of rTg4510B6 mice could be attributed to increased
phosphorylation of endogenous mouse tau rather than
transgenic human tau. Regardless, the enhanced murine
tau phosphorylation does not appear to alter to ultimate
neurodegenerative phenotype observed in rTg4510B6
mice. Interestingly, it has been reported that Dab1 deficient
mice on a C57BL/6 strain background have increased
murine tau phosphorylation compared to Dab1 deficient
mice on a BALB/cByJ strain background [42]. Further, the
increased murine phospho-tau has been correlated with
higher expression of a novel modifier of tau phosphoryl-
ation, Stk25, in C57BL/6 mice [43]. In Dab1 deficient mice
on a C57BL/6 background, increased phosphorylation of
mouse tau was not associated with overt neurodegenera-
tion. These findings highlight a critical consideration when
studying phospho-tau alterations in mice that contain both
mouse and human tau.
Conclusions
Here we report that introduction of the C57BL/6 strain
into the rTg4510 mouse background minimally alters the
presentation of tau pathology that was originally reported
in rTg4510 on the F1 FVB/129 background. At 2.5 months
of age, rTg4510B6 mice had minor increases in human tau
expression compared to rTg4510 mice, but cognitive de-
cline and phosphorylation of tau was equivalent in rTg4510
mice on both strain backgrounds. Late stage tauopathy in
rTg4510B6 mice was robust with equivalent insoluble tau
aggregation and gross neurodegeneration to rTg4510 mice.
Additionally, we observed minor, but significant, increases
in tau phosphorylation in both older rTg4510B6 mice ascompared to rTg4510 mice, and in older NTB6 mice as
compared to NT mice. Overall, these studies provide
evidence that rTg4510 mice can be crossed to a B6/NTac
background without loss or delay of the original phenotype.
Methods
Mice
The generation of the rTg4510 mouse model that uses a
system of responder and activator transgenes to express
human mutant (P301L) tau has been previously described
[2]. Briefly, mice carrying a responder gene with human
tauP301L cDNA downstream of a tetracycline response
element (TRE) were maintained on an FVB/N background
while mice carrying an activator gene with the tetracycline
transactivator (tTA) downstream of a calcium/calmodulin
kinase IIα (CaMKIIα) promoter were maintained on a
129S6 background (tTA129S). TRE-tau responder mice are
crossed with tTA129S activator mice to produce rTg4510
mice on an F1 FVB/129S background with human mutant
tau expression focused within forebrain. tTA129S mice were
obtained by crossing offspring carrying the CaMKIIα-tTA
transgene [8] with 129S6/SvEv mice purchased from
Taconic [2] (Figure 1). The original tTA129S mice were
acquired from George Carlson. Concurrently, tTA
mice were maintained on a B6 background (tTAB6) by
crossing the CaMKIIα-tTA mice [8] to C57BL/6NTac
mice (Taconic) for more than ten generations [44]. The
original tTAB6 mice were acquired from Li-Huei Tsai.
To test the effects of the B6 strain background on the
progression of tauopathy in the rTg4510 mouse model,
we crossed TRE-tau responder mice to tTAB6 activator mice
to produce rTg4510B6 mice on an F1 FVB/B6 genetic back-
ground (Figure 1). The initial characterization of rTg4510
indicated that single transgenic (tau only and tTA only) and
non-transgenic (NT) littermates have similar performances
in Morris water maze, so to maximize the number of
rTg4510 mice that could be run within the same test,
only NT mice were used as controls. Cohorts included
2.5-, 6.5-and 10.5-month-old rTg4510, rTg4510B6 and
NT littermates of both sexes (see Table 4 for details).
Grubb’s analysis of the western blot of sarkosyl-insoluble
tau (see protocol below) identified one 2.5-month-old
Table 4 Age, number and sex of mice used in each
experimental procedure
Age Analysis rTg4510B6 NTB6 rTg4510 NT
2.5 Months MWM 5 F 3 F, 2 M 2 F, 3 M 2 F, 3 M
WB 6 F, 4 M 1 F, 1 M 5 F, 4 M 1 F, 1 M
6.5 Months WB 2 F, 1 M - 4 F -
IHC 2 F, 1 M 3 M 5 F 5 F, 2 M
10.5 Months WB 1 F, 2 M 2 M 2 F, 2 M 1 F, 1 M
IHC 1 F, 3 M 4 M 2 F, 3 M 3 F, 2 M
Key: MWM=Morris water maze; WB =Western blot; IHC = Immunohistochemistry;
NT = Non-transgenic; F = Female; M =Male.
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high tau aggregation. All western blot data from this
mouse was excluded from the final results as this may
have been a tissue preparation error.
Mice were housed and treated in accordance with the
NIH Guide for the Care and Use of Laboratory Animals.
All animal procedures were approved and conducted in
accordance with the Mayo Clinic Institutional Animal
Care and Use committee and the University of Florida
Animal Care and Use committee. Mice were maintained
in a pathogen-free facility on a 12 hour light/dark cycle
with water and food provided ad libitum.
Morris water maze
rTg4510, rTg4510B6 and NT littermates of both sexes
underwent Morris water maze (MWM) testing at
2.5 months of age. Mice were handled for 6 days prior
to the initiation of behavioral training. MWM testing
was performed in a 60 cm high and 1.5 m diameter
circular pool filled with water maintained between 24
and 26°C and that was made opaque using non-toxic
paint. The swim path of each mouse was recorded by a
video camera suspended 2.5 m over the center of the pool
and connected to the video tracking system (HVS Image
Advanced Tracker VP2000, HVS Image, Buckingham, UK).
Curtains surrounding a portion of the pool were used to
block the view of the computer. Both the curtains and
walls of the room contained dark, geometric shapes to
be used as visual cues.
MWM testing occurred over 6 consecutive days with
task acquisition training on days 1 through 5 and with
probe trials to evaluate spatial memory on day 3, prior to
the onset of the training session, and on day 6. For training
sessions, a 15 cm diameter platform was submerged 1 cm
under the surface of the water in the middle of the target
quadrant. The hidden escape platform was located in the
same target quadrant for each session for each mouse. The
mouse was transported to the pool in a holding container
and released facing the wall of the pool from each of
the cardinal directions in a semi-random fashion. Once
released, the mouse had 60 seconds to locate the hiddenplatform. If a mouse failed to find the platform, then it
was gently guided to the platform and each mouse was
allowed to remain on the platform for 10 seconds. Each
mouse received 4 training trials per day. During the probe
trials on days 3 and 6, the hidden platform was removed
from the pool and each animal searched for the hidden
platform for 60 seconds.
Prior to the start of the MWM, the 2.5-month-old cohort
underwent a visible cued test to evaluate sensorimotor func-
tion. A curtain surrounded the MWM tank so that spatial
cues could not be referenced and a platform 0.5 cm above
the water that contained a visual cue (a tall black rod) was
placed in the tank. Both the quadrant location of the visible
cued platform and the mouse release points were changed
semi randomly for each trial to prevent habituation to a par-
ticular quadrant. Mice were given 90 seconds to reach the
platform before being gently guided to the platform where
the mice remained for 10 seconds. Each mouse was tested 4
times per day for 3 days.
Tissue harvest and preparation
Mice were euthanized by cervical dislocation and the
brains were rapidly removed and cut down the midline.
The left hemisphere was drop fixed in 10% formalin for
immunohistochemical analysis and the right hemisphere
was frozen on dry ice and then stored at−80°C. For tau
biochemical analysis, sarkosyl fractionation was performed
on the frozen brains as previously described [2]. Specifically,
each whole hemisphere was homogenized in 10 volumes
of homogenate buffer [50 mM Tris–HCl, 274 mM NaCl,
5 mM KCl, 1% protease inhibitor mixture (Sigma), 1%
phosphatase inhibitor cocktails I and II (Sigma), and 1 mM
phenylmethylsulfonyl fluoride (PMSF), (pH 8.0)] and 200 μl
of homogenate was then centrifuged at 150,000 x g for
15 minutes at 4°C. The supernatant, which contains
the soluble tau species, was collected and the protein
concentration determined using a standard BCA protein
assay (Pierce). Pellets were further homogenized in 3
volumes (600 μl) of Buffer B [10 mM Tris–HCl (pH 7.4),
0.8 M NaCl, 10% Sucrose, 1 mM EGTA and 1 mM PMSF]
and centrifuged for 15 minutes at 150,000 x g at 4°C. The
supernatants were incubated with 1% sarkosyl (Sigma) for
one hour at 37°C and then centrifuged at 150,000 x g for
30 minutes at 4°C. The sarkosyl-insoluble pellet was re-
suspended in 20 μl TE buffer [10 mM Tris–HCl (pH 8.0),
1 mM EDTA] to obtain the biochemical equivalent of
neurofibrillary tangles.
Antibodies
Tau antibodies used included the polyclonal antibody E1
(specific for amino acids 19-33 of human tau) [45] and
the monoclonal antibody Tau5 (provided by Dr. Lester I.
Binder, Northwestern University Medical School) for
western blot analysis and the monoclonal tau antibodies
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pS396/404 tau) (provided by Dr. Peter Davies, The
Einstein Institute for Medical Research, Manhasset, NY)
for both western blot and immunohistochemical analysis.
Anti-GAPDH (Biodesign) was used as a loading control
for western blot analysis.
Western blotting
For tau protein analysis, 1-5 μg of the soluble fraction and
3 μl (6.5-and 10.5-month-old mice) or 4.5 μl (2.5-month-
old mice) of the sarkosyl-insoluble fraction were loaded in
each well. Brain lysates were diluted in Novex Tris-glycine
SDS-sample buffer (Invitrogen) with β-mercaptoethanol
and heat denatured at 95°C for 5 minutes before being
loaded onto 26-well 10% Tris-glycine gels (Invitrogen) and
separated by SDS-PAGE. Protein was transferred in CAPS
transfer buffer (Sigma) to PVDF membranes. Membranes
were then blocked in Tris buffered saline plus 0.1%
TritonX-100 (TBS-T) with 5% non-fat milk and incubated
overnight with antibody diluted in TBS-T/5% milk. Mem-
branes were washed in TBS-T, incubated with peroxidase-
conjugated goat anti-mouse HRP or goat anti-rabbit HRP
secondary antibodies (Jackson ImmunoResearch) for 1
hour at room temperature and washed again in TBS-T.
Membranes were developed using Western Lightning
Plus (Perkin Elmer) and imaged using a FluorChem E
System (ProteinSimple). The relative levels of immu-
noreactivity were determined by densitometry using
the software AlphaView SA (ProteinSimple). Relative
soluble tau and phospho-tau levels were quantified by
normalizing protein levels to GAPDH levels. The relative
levels of phospho-tau in the sarkosyl-insoluble fraction were
determined by normalizing CP13 and PHF1 levels with E1
levels and Tau5 levels (data not shown) for each mouse to
correct for the amount of tau aggregated in the sarkosyl-
insoluble fraction of that animal. Tau and phospho-tau
levels are presented relative to 6.5-month-old rTg4510 mice
for the older cohorts (6.5 and 10.5 months of age) and
relative to 2.5-month-old rTg4510 mice for the young
cohort (2.5 months of age).
Immunohistochemical analysis
Fixed mouse brains were paraffin embedded and cut into
5 μm sagittal sections. Hematoxylin and eosin (H&E) stain-
ing was performed on at least two brain sections from each
mouse to align all brains to approximately 1.3 mm lateral
to the midline using a mouse brain atlas [46]. Stained slides
were digitally scanned using a Scanscope XT scanner.
Hippocampal area measurements were performed on a
sagittal section stained with H&E obtained for each mouse.
The hippocampal formation was then outlined using
ImageScope version 10 software (Aperio, Vista, CA) and
the resultant area value for each animal was used to gener-
ate group means. The same section used for hippocampalarea measurements per animal was also used to calculate
the CA1 index. Three lines were pseudo-randomly drawn
perpendicular to the main axis of the CA1 cell layer and
the number of intact neuronal cell bodies touching each
line was blindly counted. Each of the counts was summed
to obtain a “CA1 index” value per animal.
Standard immunohistochemical procedures were used
to immunostain tissues with PHF1 and CP13 antibodies
and counterstain with hematoxylin using the Dako
Universal Autostainer with DAKO Envision + HRP
system (Dako). Stained slides were digitally scanned
using a Scanscope XT scanner and were analyzed using
ImageScope software. Positive pixel count algorithms were
created to measure the percent positivity of the secondary
antibody, specifically chromogen DAB, in a selected re-
gion. Distinct algorithms were used for burden analysis of
each primary antibody in either rTg4510 or NT litter-
mates. The brain regions analyzed included the cortex and
the hippocampal formation, which expressed high levels
of human tau, and the brain stem, which has very low
human tau expression in rTg4510 mice.
Statistical analysis
Results for MWM training are displayed as the group
mean ± SEM and were analyzed using multifactorial re-
peated measures (RM) ANOVA, with strain background
and genotype as between subject factors and training days
as within subject factors. When appropriate, post hoc
comparisons were performed. The probe trial for MWM
was analyzed using two-way ANOVA (genotype x strain)
with post hoc Bonferroni’s multiple comparisons test.
Western blot results from 2.5-month-old mice were
analyzed with an unpaired, two tailed Student’s t-test.
Assessments of gross neuropathology in 6.5- and 10.5-
month-old rTg4510 and rTg4510B6 mice and NTB6 litter-
mates were analyzed using one-way ANOVA with post hoc
analysis with Bonferroni’s multiple comparison tests.
Western blot and IHC data from 6.5- and 10.5-month-old
rTg4510 and rTg4510B6 mice were analyzed using two-way
ANOVA with strain background and age as independent
variables and post hoc analysis with Bonferroni’s multiple
comparison test. Grubb’s analysis was used to identify out-
liers in the western blot analysis of sarkosyl-insoluble tau.
Analyses were performed using GraphPad Prism version
6.00 software (GraphPad Software) and SPSS version 20.0
(IBM). In all cases, p < 0.05 was considered to be statisti-
cally significant.
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